CD274 and neoplasm: Fang et al.75 used similar methods in their study, where they developed a chemokine/anti-PD-L1 nanobody fusion protein that simultaneously targeted exhausted immune cells and exclusion immune cells (i.e., immune cells close to the tumor but few that directly contact tumor cells)76.